Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

Insmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its ...

Millions are affected by lung conditions, often unaware of risks. Asthma + Lung UK's Andy Whittamore shares tips for ...

interstitial lung disease, bronchiectasis, benign and malignant neoplasms, and lung transplantation. The Lung Institute has developed a comprehensive program across specialties with one site for ...

The Lung Transplant Program at Baylor St. Luke’s Medical Center is a national leader in advanced lung disease and offers a variety of options for patients in need of a lung transplant. Our team is led ...

Bronchiectasis is a chronic lung disease where the bronchi become widened permanently due to infection, inflammation, and lung tissue damage. Brensocatib is a novel, small molecule, reversible ...

It is estimated that some 300,000 people in the UK have bronchiectasis, a devastating chronic lung condition that causes excess mucus to build up in the lungs, resulting in frequent coughing and ...

One of the big medical coin flips of the season landed heads-up on Tuesday, sending shares of the biotech Insmed up more than ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...